Objectives-To determine the effects of enoximone on mortality and quality of life in patients with severe end stage heart failure. Design-A randomised, double blind, placebo controlled trial of the addition of enoximone to conventional treatment.
Abstract
Objectives-To determine the effects of enoximone on mortality and quality of life in patients with severe end stage heart failure. Design-A randomised, double blind, placebo controlled trial of the addition of enoximone to conventional treatment. Planned minimum follow up of one year. Setting--District general hospitals and cardiological referral centres in the United Kingdom. Patients-Planned 200 patients with severe, symptomatic heart failure despite treatment with diuretics and where appropriate and tolerated angiotensin converting enzyme inhibitors and digoxin.
Results-The study was ended early by the ethics committee after 151 patients had been recruited because of an excess mortality in the enoximone group: 27 deaths compared with 18 in the placebo group (P < 0.05). Quality of life measured with a disease specific questionnaire showed a clinically significant improvement at week 2 with a mean increase score of 0-48 in the enoximone treated patients compared with 0-14 in those receiving placebo (P = 0.0086).
With the Nottingham health profile questionnaire the physical mobility score was improved after three months in the enoximone group, median 21-3 compared with 41*8 in the placebo group (P = 0-008).
Conclusions-In patients with severe heart failure who remain incapacitated despite conventional treatment enoximone reduced survival but had a beneficial effect on the quality of life. Drugs that improve symptoms in severe end stage heart failure should not be discarded lightly. (Br HeartJ 1994; 72:226-230) Heart failure is common and is probably becoming more common. It imposes a huge burden of morbidity and mortality on patients and an ideal treatment would therefore improve both symptoms and survival. Although angiotensin converting enzyme (ACE) inhibitors reduce symptoms and have a favourable effect on prognosis,1'-even with this treatment almost all patients continue to have an impaired capability for exercise and many remain severely incapacitated. Cardiac transplantation is effective in improving symptoms and survival in those who remain severely incapacitated, but this option is only available for a small minority of patients. The treatment of most patients with severe heart failure remains difficult.
Enoximone is an orally active cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitor and by this mechanism has inotropic and vasodilator properties. It has been shown to improve the symptoms and exercise capability of patients with severe heart failure who remain symptomatic despite optimum treatment with diuretics and ACE inhibitors.4 Although retrospective analysis of one exercise study suggested that it may be associated with an adverse effect on survival5 no prospective trial has been completed which has specifically attempted to determine the effects of enoximone on mortality. 5 The Prospective Randomised Milrinone Survival Evaluation (PROMISE) trial clearly showed that milrinone, another cAMP PDE inhibitor, caused a reduced survival, a higher rate of adverse events, and no symptomatic improvement in patients with severe heart failure.6 It is not known whether the adverse effect on survival is limited to milrinone or is a class effect, and it is not known whether other cAMP PDE inhibitors may cause an improvement in symptoms. The purpose of this study was to examine the effect of enoximone treatment given by mouth on mortality and quality of life in a group of patients with severe heart failure who remained severely incapacitated despite optimum treatment with diuretics and ACE inhibitors. Recruitment to the study was started a year before the results of the PROMISE trial became known. 
Endpoints
The primary endpoint of the study was the number of days to death for each patient, assessed on an intention to treat basis. Survival times were censored for patients alive at the end of the study at the date last seen and for the patients lost to follow up at the date last known to be alive. All deaths were treated equally in the intention to treat analysis irrespective of previous withdrawal and whatever the cause of death. Survival curves for the two groups were estimated using the KaplanMeier procedure and compared using a log rank test. Analysis using a proportional hazards model was also performed to estimate the Table 1 shows the baseline demography for the patients at randomisation. For all major variables the groups were well matched. All but eight patients were being treated with ACE inhibitors and in these an ACE inhibitor had been tried but had not been tolerated. A total of 23% were in NYHA class IV and consistent with this the median dose of frusemide was 160 mg daily. The mean cardiothoracic ratio was 60%. These characteristics indicate that the trial achieved its objectives of including very ill patients. TRIAL 
DRUGS
One hundred and three patients were titrated to 100 mg three times a day after two weeks and were maintained on this dose. In 27 patients the dose was not increased above 50 mg three times a day and in the remaining patients the dose varied throughout the study. Because of the small number of patients included in the trial and the fact that no subgroup was specified in the protocol, the analysis of subgroups can only be thought of as exploratory. There was a significant excess mortality in the enoximone treated patients, however, with a baseline heart rate of greater than 85 beats/minute (P = 0 0036) in those with heart failure of less than two years' duration (P = 0 045) and those with a diuretic requirement of greater than 120 mg frusemide daily (P = 0 040). Conversely, the only subgroup with a lower but non-significant observed mortality in patients receiving enoxi-500 600 mone were those with a heart rate of less than 85 beats/minute (P = 0 79). those patients receiving enoximone and 149 days for those receiving placebo (p = 0 044). for those patients In total there were 156 admissions to hospital ,ne) (P = 0044).
and of these 67 were due to worsening heart failure (37 enoximone and 30 placebo) and 10 due to a dysrhythmia (four enoximone and six placebo).
QUALITY OF LIFE difference between enoximone and placebo P = 0-008. 0 0086), indicating an improved quality of life, whereas there was no statistically significant change for the placebo group, 0-14. There was no other significant difference thereafter, probably because of the reduced numbers of patients continuing in the trial, although the mean values for the enoximone treated patients were always higher. Table 3 gives the median physical mobility scores from the Nottingham health profile questionnaire. Measured with this questionnaire a reduction in score indicates an improved quality of life. With the Nottingham health profile, as with the disease specific questionnaire, the enoximone group was more severely symptomatic than the placebo group. Once treatment began, however, there were fewer problems with physical mobility in the enoximone group throughout the study. This difference reached statistical significance at month 3 with respect to change from baseline (P = 0 008).
There was no difference in NYHA classification between the groups at any time during the study.
Discussion
This trial has shown an excess mortality with a cAMP PDE inhibitor in patients with severe heart failure, but it raises the much wider question of what we are trying to achieve in treating these patients. In patients with mild symptoms improvement in survival is obviously the prime objective. In more severely ill patients with distressing if not disabling symptoms, this may no longer be so and an improvement in their quality of life may be more important. These severely symptomatic patients may even be prepared to risk a reduced life expectancy for an improvement in their quality of life. In this situation the results of this study suggest that enoximone may be a useful drug for the treatment of heart failure.
The Enoximone also appeared to worsen survival in those patients who had had heart failure for comparatively shorter periods of time, whereas in those with heart failure of longer duration there was no adverse effect.
Admission to hospital also occurred sooner in the patients treated with enoximone. The numbers included in the trial do not allow reliable analysis of different mechanisms of death, but there was a twofold increase in sudden death in the patients treated with enoximone compared with those receiving placebo, whereas there was a similar risk of death due to progressive heart failure. An excess of sudden death was also seen in the PROMISE trial. In those patients with a tachycardia before randomisation enoximone caused a considerable excess risk of death, whereas the only patients in whom there was no evidence of a deleterious effect were those with a comparatively slow heart rate. The excess mortality in this study in patients with a tachycardia may also be because these patients had more severe heart failure and this is supported by the fact that the risk of death was higher in those patients receiving larger doses of diuretics. In the PROMISE trial it was also the more severely ill patients who seemed to be harmed by milrinone.
Although the results of this study are in agreement with the PROMISE trial and therefore suggest that the adverse effect on survival is a class effect of cAMP PDE inhibitors, the important difference is that enoximone in this trial caused an improvement in symptomatic wellbeing. In severely symptomatic patients this should not be dismissed lightly. In patients who are less symptomatic an improvement in survival is the primary aim of treatment, but in more severely ill patients the same may not apply. In such patients increased survival may be a secondary concern and it is likely that the patients themselves would prefer an improved quality of life at the expense of reduced sur-vival. This may not result only from treatment with cAMP PDE inhibitors and we must be careful not to discard drugs which may be of considerable symptomatic benefit in patients with severe heart failure. 
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